Literature DB >> 25667998

Anticoagulation therapy: Balancing the risks of stroke and bleeding in CKD.

Arman Qamar1, Deepak L Bhatt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25667998     DOI： 10.1038/nrneph.2015.14

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.

Authors:  Ziad Hijazi; Stefan H Hohnloser; Jonas Oldgren; Ulrika Andersson; Stuart J Connolly; John W Eikelboom; Michael D Ezekowitz; Paul A Reilly; Agneta Siegbahn; Salim Yusuf; Lars Wallentin
Journal:  Circulation       Date:  2013-12-09       Impact factor: 29.690

2.  Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.

Authors:  Mitesh Shah; Meytal Avgil Tsadok; Cynthia A Jackevicius; Vidal Essebag; Mark J Eisenberg; Elham Rahme; Karin H Humphries; Jack V Tu; Hassan Behlouli; Helen Guo; Louise Pilote
Journal:  Circulation       Date:  2014-01-22       Impact factor: 29.690

3.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.

Authors:  Stefan H Hohnloser; Ziad Hijazi; Laine Thomas; John H Alexander; John Amerena; Michael Hanna; Matyas Keltai; Fernando Lanas; Renato D Lopes; Jose Lopez-Sendon; Christopher B Granger; Lars Wallentin
Journal:  Eur Heart J       Date:  2012-08-29       Impact factor: 29.983

4.  Stroke and bleeding in atrial fibrillation with chronic kidney disease.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Anne-Lise Kamper; Kristine Hommel; Lars Køber; Deirdre A Lane; Jesper Lindhardsen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

5.  Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.

Authors:  Keith A A Fox; Jonathan P Piccini; Daniel Wojdyla; Richard C Becker; Jonathan L Halperin; Christopher C Nessel; John F Paolini; Graeme J Hankey; Kenneth W Mahaffey; Manesh R Patel; Daniel E Singer; Robert M Califf
Journal:  Eur Heart J       Date:  2011-08-28       Impact factor: 29.983

6.  Warfarin in atrial fibrillation patients with moderate chronic kidney disease.

Authors:  Robert G Hart; Lesly A Pearce; Richard W Asinger; Charles A Herzog
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

7.  Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.

Authors:  Anders Nissen Bonde; Gregory Y H Lip; Anne-Lise Kamper; Peter Riis Hansen; Morten Lamberts; Kristine Hommel; Morten Lock Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Jonas Bjerring Olesen
Journal:  J Am Coll Cardiol       Date:  2014-12-16       Impact factor: 24.094

8.  Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.

Authors:  Kevin E Chan; J Michael Lazarus; Ravi Thadhani; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

9.  Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Authors:  Juan Jesús Carrero; Marie Evans; Karolina Szummer; Jonas Spaak; Lars Lindhagen; Robert Edfors; Peter Stenvinkel; Stefan H Jacobson; Tomas Jernberg
Journal:  JAMA       Date:  2014-03-05       Impact factor: 56.272
  9 in total
  6 in total

1.  Reply: Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe?

Authors:  Arman Qamar; Deepak L Bhatt
Journal:  Nat Rev Nephrol       Date:  2015-07-07       Impact factor: 28.314

2.  Challenging the use of warfarin in patients on dialysis with atrial fibrillation.

Authors:  Georg Schlieper; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2015-07-07       Impact factor: 28.314

Review 3.  Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?

Authors:  Benjamin E Peterson; Deepak L Bhatt
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

4.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Mintu P Turakhia; Peter J Blankestijn; Juan-Jesus Carrero; Catherine M Clase; Rajat Deo; Charles A Herzog; Scott E Kasner; Rod S Passman; Roberto Pecoits-Filho; Holger Reinecke; Gautam R Shroff; Wojciech Zareba; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christoph Wanner
Journal:  Eur Heart J       Date:  2018-06-21       Impact factor: 29.983

5.  The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients: A systemic review and meta-analysis.

Authors:  Yi-Yue Gui; Song Zou; Wen-Long Yang; Shen-Zhen Gong; Zhi-Fu Cen; Zhong-Hui Xie; Kai-Jun Cui
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

6.  Modulation of stroke risk in chronic kidney disease.

Authors:  Julia Arnold; Don Sims; Charles J Ferro
Journal:  Clin Kidney J       Date:  2015-12-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.